

**Table B Randomised controlled trials of cholesterol reduction by any means other than statins and disease events: individual trial data**

Trial (acronym¶)	Cholesterol lowering method	No of participants		Mean LDL reduction cholesterol (mmol/l)	Ischaemic heart disease events by time period:										Strokes:			
					≤ 1 year		1.1-2 years		2.1 - 5 years		> 5 years		all		fatal			
					tr	plac	tr	plac	tr	plac	tr	plac	tr	plac	tr	plac	tr	plac
<b>Without known vascular disease on entry</b>																		
Helsinki	gemfibrozil	2051	2030	0.5	14	13		13	15	28	53	1	3	-	-	6	4	
SENDCAP <sup>w196</sup>	bezafibrate	81	83	0.3		1 3 ‡				1	1	-	-	0	0	0	0	
WHO	clofibrate	5331	5296	0.6	25	27		27	29	75	91	46	63	31	24	13	11	
LRC	resin	1906	1900	0.9	30	19		16	32	51	66	58	70	17	14	3	2	
Upjohn†	resin	1149	1129	0.4	8	13		6	12	5	6	-	-	-	-	1	4	
Minnesota	diet	4541	4516	0.7	77	63		24	26	30	32	-	-	-	-	22	21	
Los Angeles†	diet	424	422	0.7	9	8		9	14	23	27	11	16	13	22	3	9	
<b>With known vascular disease on entry</b>																		
Helsinki 2	gemfibrozil	311	317	0.3		10 14 ‡				25	10	-	-	-	-	1	1	
LOCAT <sup>w197</sup>	gemfibrozil	197	198	0.4		4 4 ‡				-	-	-	-	0	0	0	0	
LEADER <sup>w198,w199</sup>	bezafibrate	783	785	0.2	27	29*		23	34	40	48	-	-	47	40	60	49	
DAIS <sup>w200</sup>	fenofibrate	207	211	0.2	5	2		0	2	3	7	-	-	0	0	0	0	
Newcastle	clofibrate	244	253	0.6	±	±		±	±	54	85	-	-	5	7	1	0	
Scottish	clofibrate	350	367	0.6	±	±		±	±	54	75	-	-			3	2	
Begg et al	clofibrate	76	79	0.5	2	4		1	2	4	13	-	-	4	5	0	1	
CDP	clofibrate	1103		0.4	74			61		128		46		80	109	20	14	
	niacin	1119	2789	0.6	73	198		56	161	126	372	32	108					
Stockholm	clofibrate, niacin	279	276	0.8	18	21 *		19	20	36	60	-	-	6	5	5	1	
VADL	niacin	145	284	0.6						14	21	-	-	-	-	1	2	
CLAS	niacin, resin	94	94	1.7		1 5 ‡								-	-	0	0	
NHLBI	resin	57	59	1.3	1	2		2	1	3	7	0	1	-	-	0	0	
POSCH	ileal bypass surgery	421	417	1.7	25	17		11	14	15	42	30	53	-	-	1	2	
DART	diet	1018	1015	0.3		132 144 ‡								-	-	4	3	
Oslo	diet	229	229	1.1	11	17		17	17	33	47	-	-	-	-	1	1	

¶The expansion of the acronyms is given in the citations; expansion of acronyms and citations of unreferenced studies are given in our earlier publication<sup>6</sup>

\*Numbers of ischaemic heart disease events by time period estimated from published survival curves

†Some participants had disease on entry

‡In these trials numbers of events were available for the first two years but not the first and second years separately

±Numbers of events in years 0-2 not separately available and combined with years 2.1-5